Literature DB >> 8591045

The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.

G Spraggon1, C Phillips, U K Nowak, C P Ponting, D Saunders, C M Dobson, D I Stuart, E Y Jones.   

Abstract

BACKGROUND: Urokinase-type plasminogen activator (u-PA) promotes fibrinolysis by catalyzing the conversion of plasminogen to the active protease plasmin via the cleavage of a peptide bond. When localized to the external cell surface it contributes to tissue remodelling and cellular migration; inhibition of its activity impedes the spread of cancer. u-PA has three domains: an N-terminal receptor-binding growth factor domain, a central kringle domain and a C-terminal catalytic protease domain. The biological roles of the fibrinolytic enzymes render them therapeutic targets, however, until now no structure of the protease domain has been available. Solution of the structure of the u-PA serine protease was undertaken to provide such data.
RESULTS: The crystal structure of the catalytic domain of recombinant, non-glycosylated human u-PA, complexed with the inhibitor Glu-Gly-Arg chloromethyl ketone (EGRcmk), has been determined at a nominal resolution of 2.5 A and refined to a crystallographic R-factor of 22.4% on all data (20.4% on data > 3 sigma). The enzyme has the expected topology of a trypsin-like serine protease.
CONCLUSIONS: The enzyme has an S1 specificity pocket similar to that of trypsin, a restricted, less accessible, hydrophobic S2 pocket and a solvent-accessible S3 pocket which is capable of accommodating a wide range of residues. The EGRcmk inhibitor binds covalently at the active site to form a tetrahedral hemiketal structure. Although the overall structure is similar to that of homologous serine proteases, at six positions insertions of extra residues in loop regions create unique surface areas. One of these loop regions is highly mobile despite being anchored by the disulphide bridge which is characteristic of a small subset of serine proteases namely tissuetype plasminogen activator, Factor XII and Complement Factor I.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8591045     DOI: 10.1016/s0969-2126(01)00203-9

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  22 in total

1.  Structural similarity of the covalent complexes formed between the serpin plasminogen activator inhibitor-1 and the arginine-specific proteinases trypsin, LMW u-PA, HMW u-PA, and t-PA: use of site-specific fluorescent probes of local environment.

Authors:  Marija Backovic; Efstratios Stratikos; Daniel A Lawrence; Peter G W Gettins
Journal:  Protein Sci       Date:  2002-05       Impact factor: 6.725

2.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

3.  (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.

Authors:  S Sperl; U Jacob; N Arroyo de Prada; J Stürzebecher; O G Wilhelm; W Bode; V Magdolen; R Huber; L Moroder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.

Authors:  Newton J Hurst; Abdo J Najy; Carolyn V Ustach; Lisa Movilla; Hyeong-Reh Choi Kim
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

5.  Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.

Authors:  Zhonghui Lin; Longguang Jiang; Cai Yuan; Jan K Jensen; Xu Zhang; Zhipu Luo; Barbara C Furie; Bruce Furie; Peter A Andreasen; Mingdong Huang
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

6.  Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors.

Authors:  Agnieszka Jendroszek; Jeppe B Madsen; Andrés Chana-Muñoz; Daniel M Dupont; Anni Christensen; Frank Panitz; Ernst-Martin Füchtbauer; Simon C Lovell; Jan K Jensen
Journal:  J Biol Chem       Date:  2019-01-16       Impact factor: 5.157

7.  Reprogramming urokinase into an antibody-recruiting anticancer agent.

Authors:  Charles E Jakobsche; Patrick J McEnaney; Andrew X Zhang; David A Spiegel
Journal:  ACS Chem Biol       Date:  2011-11-18       Impact factor: 5.100

8.  A novel mode of intervention with serine protease activity: targeting zymogen activation.

Authors:  Grant E Blouse; Kenneth A Bøtkjaer; Elena Deryugina; Aleksandra A Byszuk; Janni M Jensen; Kim K Mortensen; James P Quigley; Peter A Andreasen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

9.  The molecular basis of urokinase inhibition: from the nonempirical analysis of intermolecular interactions to the prediction of binding affinity.

Authors:  Renata Grzywa; Edyta Dyguda-Kazimierowicz; Marcin Sieńczyk; Mikołaj Feliks; W Andrzej Sokalski; Józef Oleksyszyn
Journal:  J Mol Model       Date:  2007-03-20       Impact factor: 1.810

10.  In vitro fibrinolysis and antithrombosis characterizations of novel recombinant microplasminogen with RGD and GPRP peptides.

Authors:  Wu Chen; Yi Li; Pin Chen; Maocai Wu; Lihua Wang; Hua Zhang; Laiyou Wang
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.